Xencor (XNCR) Total Liabilities (2013 - 2026)
Xencor (XNCR) reported Total Liabilities of $221.2 million for Q1 2026, down 16.47% year-over-year from $264.8 million in Q1 2025, and down 7.79% quarter-over-quarter from $239.9 million in Q4 2025.
Xencor (XNCR) Total Liabilities (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Total Liabilities data on file, last reported at $221.2 million in Q1 2026.
- Total Liabilities for Q1 2026 came in at $221.2 million, down 16.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $221.2 million (down 16.47% YoY), and the FY2025 annual result was $239.9 million, down 13.68% from the prior year.
- Total Liabilities fell to $221.2 million in Q1 2026 per XNCR's latest filing, from $239.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $303.0 million in Q4 2023 and troughed at $94.9 million in Q1 2022.
- A 5-year average of $203.3 million and a median of $239.9 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities soared 194.13% in 2024, then dropped 17.17% in 2025.
- A 5-year view of Total Liabilities shows it stood at $118.8 million in 2022, then soared by 155.16% to $303.0 million in 2023, then slipped by 8.29% to $277.9 million in 2024, then decreased by 13.68% to $239.9 million in 2025, then dropped by 7.79% to $221.2 million in 2026.
- Business Quant data shows XNCR's Total Liabilities at $221.2 million in Q1 2026, $239.9 million in Q4 2025, and $243.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 10.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 19.51 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 137.56 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 221.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 221.21 Mn |
| Dec 31, 2025 | 239.91 Mn |
| Sep 30, 2025 | 243.50 Mn |
| Jun 30, 2025 | 259.07 Mn |
| Mar 31, 2025 | 264.82 Mn |
| Dec 31, 2024 | 277.92 Mn |
| Sep 30, 2024 | 293.98 Mn |
| Jun 30, 2024 | 291.91 Mn |
| Mar 31, 2024 | 297.12 Mn |
| Dec 31, 2023 | 303.05 Mn |
| Sep 30, 2023 | 109.42 Mn |
| Jun 30, 2023 | 99.25 Mn |
| Mar 31, 2023 | 119.83 Mn |
| Dec 31, 2022 | 118.77 Mn |
| Sep 30, 2022 | 112.57 Mn |
| Jun 30, 2022 | 108.98 Mn |
| Mar 31, 2022 | 94.90 Mn |
| Dec 31, 2021 | 104.71 Mn |
| Sep 30, 2021 | 78.40 Mn |
| Jun 30, 2021 | 48.66 Mn |